Los Angeles Capital Management’s Kymera Therapeutics KYMR Stock Holding History

Los Angeles Capital Management’s Portfolio KYMR Stock Details KYMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$394K	Buy	4,730 +2,762	+140%	+$219K	﹤0.01%	947
2025 Q4	$121K	Buy	+1,968	New	+$133K	﹤0.01%	1370
2024 Q2	–	Sell	-5,911	Closed	-$238K	–	1233
2024 Q1	$238K	Sell	5,911 -3,737	-39%	-$134K	﹤0.01%	1069
2023 Q4	$246K	Buy	+9,648	New	+$173K	﹤0.01%	1063
2023 Q3	–	Sell	-9,648	Closed	-$222K	–	1183
2023 Q2	$222K	Buy	+9,648	New	+$276K	﹤0.01%	1098

Other funds holding KYMR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Los Angeles Capital Management's KYMR Position: Q1 2026 in Review

Los Angeles Capital Management increased its Kymera Therapeutics (KYMR) stake by 140% in Q1 2026, buying an estimated $219K and bringing the position to 4,730 shares worth $394K. The position accounts for ﹤0.01% of the portfolio, ranked #947.

Los Angeles Capital Management first reported a position in KYMR in Q2 2023 and has held it in 5 quarters since. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

Los Angeles Capital Management held 4,730 shares of Kymera Therapeutics worth $394K as of Q1 2026.
Los Angeles Capital Management bought 2,762 Kymera Therapeutics shares in Q1 2026, an estimated $219K.
Kymera Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #947 holding.
Los Angeles Capital Management first reported a position in Kymera Therapeutics in Q2 2023 and has held it in 5 quarters since.
256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.